About avelumabs
PD-L1 immune checkpoint inhibitor
Used for
- Merkel cell carcinoma
- Advanced renal cell carcinoma, with axitinib
- Advanced urothelial cancer in certain settings
Usual adult dose
800 mg by intravenous infusion every two weeks; some indications use weight-based dosing.
Common side effects
- Fatigue
- Infusion reactions
- Diarrhoea
- Rash
Important warnings
- Immune reactions can affect lungs, liver, bowel, hormone glands, or other organs.
- Serious infusion reactions can occur.
- Monitor for infection and immune-related side effects.
- Treatment requires specialist supervision.
Pregnancy
May harm an unborn baby. Pregnancy is generally avoided during treatment and for one month afterward.
Breastfeeding
Breastfeeding is not recommended during treatment and for one month after the last dose.
Interactions
- Other immune-activating cancer treatments may increase immune-related side effects.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.